Evaluation of the tolerance to vancomycin in 395 oxacillin-resistant Staphylococcus aureus strains isolated from Brazilian hospitals;Avaliação da tolerância à vancomicina em 395 cepas hospitalares de Staphylococcus aureus resistentes à oxacilina

Jornal Brasileiro de Patologia e Medicina Laboratorial

Volumn 37, Issue 4, 2001, Pages 239-246

  Oliveira, Geraldo A ^a,c   Okada, Sabrina S ^b   Guenta, Regiane S ^b   Mamizuka, Elsa M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fac de Cie Farmaceuticas da USP   (Brazil)

^c Hospital Universitario   (Brazil)

Author keywords

Staphylococcus aureus; Tolerance; Vancomycin

Indexed keywords

EID: 33947374872     PISSN: 16762444     EISSN: 16784774     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Aeschlimann, J.R.; Hershberger, E. & Rybak, M.J. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother., 43: 1914-8, 1999.
2. Amsterdam, D. Susceptibility testing of antimicrobials in liquid media. In: Lorian, V. Antibiotics in laboratory medicine. 3.ed. Baltimore: Williams & Wilkins, 1991. Vol. 3, p. 53-105.
3. Boyle-Vavra, S. et al. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother., 44: 272-7, 2000.
4. Bryan, L.E. & Godfrey, A.J. β-lactam antibiotics: mode of action and bacterial resistance. In: Lorian, V. Antibiotics in laboratory medicine. 3.ed., Baltimore: Williams & Wilkins, 1991. Vol. 16, p. 599-664.
5. Chambers, H.F. Methicillin-resistance in Staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev., 10: 781-91, 1997.
6. Cui, L. et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococus aureus Mu50. Antimicrob. Agents Chemother., 44: 2276-85, 2000.
7. Freitas, C.C. et al. Tolerância a antibióticos em cepas de Staphylococcus aureus isoladas de pacientes do HUAP-UFF. Arq. Bras. Med., 65: 116S, 1991.
8. Freitas, C.C. O fenômeno da tolerância bacteriana aos antibióticos. J. Bras. Doenças Sex. Transm., 1: 103-8, 1989.
9. Hanaki, H. et al. Increase in glutamine-non-amidated muropeptides in the peptidoglican of vancomycinresistant Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother., 42: 315-20, 1998.
10. Handwerger, S. & Tomasz, A. Antibiotic tolerance among clinical isolates of bacteria. Rev. Infect. Dis., 7: 368-86, 1985.
11. Hindler, J. Antimicrobial susceptibility testing. In: Isemberg, H.D. Clinical microbiology procedures handbook. Washington, D.C.: ASM Press, 1994. Vol. 1, section 5.
12. Hiramatsu, K. Vancomycin resistance in Staphylococci. Drug Resistance Updates, 1: 135-50, 1998.
13. Hiramatsu, K.; Ito, T. & Hanaki, H. Mechanisms of methicillin and vancomycin resistance in Staphylococcus aureus. Ballière's Clin. Infect. Dis., 5: 221-42, 1999.
14. Kloos, W.E. & Bannerman, T.L. Staphylococcus and Micrococcus. In: Murray, P.R. et al. Manual of clinical microbiology. 7.ed. Washington: American Society for Microbiology, 1999. Vol. 16, p. 264-82.
15. Koneman, E.W. et al. Diagnostic microbiology. 5.ed. New York: Lippincott, 1997. Vol. 15, p. 785-856.
16. Liu, H.H. & Tomasz, A. Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae. J. Infect. Dis., 152: 365-72, 1985.
17. Lowy, F.D. Staphylococcus aureus infections. N. Engl. J. Med., 339: 520-32, 1998.
18. May, J.; Shannon, K. & French, G. Glicopeptide tolerance in Staphylococcus aureus. J. Antimicrob. Chemother., 42: 189-97, 1998.
19. Musher, D.M. & Fletcher, T. Tolerant Staphylococcus aureus causing vertebral osteomielitis. Arch. Intern. Med., 142: 632-4, 1982.
20. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A5. 5.ed. Villanova, Pa., 2000. Vol. 20, n. 2.
21. Norden, C.W.; Keleti, E. Antibiotic tolerance in strains of Staphylococcus aureus. J. Antimicrob. Chemother., 7: 599-605, 1981.
22. Novak, R. et al. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature, 399: 590-3, 1999.
23. Oliveira, G.A.; Levy, C.E. & Mamizuka, E.M. Estudo do perfil de resistência de 626 cepas de Staphylococcus aureus isoladas de 25 hospitais brasileiros entre setembro de 1995 e junho de 1997. J. Bras. Pat., 36: 147-56, 2000.
24. Oliveira, G.A.; Levy, C.E. & Mamizuka, E.M. Staphylococcus aureus apresentando resistência intermediária à vancomicina: mecanismos de resistência, detecção laboratorial e perspectivas de emergência no Brasil. J. Bras. Pat., 36(2): 96-102, 2000.
25. Pelletier Jr., L.L. Lack of reproducibility of macrodilution MBCs for Staphylococcus aureus. Antimicrob. Agents Chemother., 26: 815-8, 1984.
26. Perry, J.D.; Jones, A.L. & Gould, F.K. Glicopeptide tolerance in bacteria causing endocarditis. J. Antimicrob. Chemother., 44: 121-4, 1999.
27. Peterson, L.R. et al. Medium-dependent variation in bactericidal activity of antibiotics against susceptible Staphylococcus aureus. Antimicrobiol. Agents Chemother., 13: 665-8, 1978.
28. Rajashekaraiah, K.R. et al. Clinical significance of tolerant strains Staphylococcus aureus in patients with endocarditis. Ann. Intern. Med., 93: 796-800, 1980.
29. Reis, A.G.A.C. et al. Septicemia por Staphylococcus aureus em crianças: tolerância bacteriana à vancomicina e poder bactericida do soro. Rev. Ass. Med. Brasil, 41: 47-52, 1995.
30. Reynolds, P.E. Structure, biochemistry and mode of action of glicopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis., 8: 943-50, 1989.
31. Sande, M.A. Antimicrobial therapy of infections in patients with Aids: an overview. J. Microb. Chemother., 23: 63-5, 1989.
32. Serazin, V.; Mougeot, C.; Libert, J.M. Staphylococcus aureus résistant à la méticilline et glycopeptides (vancomycine, teicoplanine): sélection de résistance in vitro. Path. Biol., 42: 323-7, 1994.
33. Sieradzki, K. & Tomasz, A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomicyn-resistant mutant of Staphylococcus aureus. J. Bacteriol., 179: 2557-66, 1997.
34. Smith, T.L. et al. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med., 340: 493-501, 1999.
35. Stratton, C.W. In vitro testing: correlations between bacterial susceptibility, body fluid levels and effectiveness of antibacterial therapy. In: Lorian, V. Antibiotics in laboratory medicine. 3.ed. Baltimore: Williams & Wilkins, 1991. Vol. 24, p. 849-79.
36. Tavares, W. Manual de antibióticos e quimioterápicos antiinfecciosos. 2.ed. São Paulo: Editora Atheneu, 1996. Vol. 5, p. 43-100.
37. Tomasz, A.; Albino, A. & Zanati, E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature, 227: 138-40, 1970.
38. Voorn, G.P. et al. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob. Agents Chemother., 38: 487-93, 1994.
39. Voorn, G.P. et al. In vitro development and stability of tolerance to cloxacillin and vancomycin in Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis., 13: 741-6, 1994.
40. Watanakunakorn, C. Antibiotic tolerance of Staphylococcus epidermidis. Scand. J. Infect. Dis., 17: 59-61, 1985.
41. Yao, J.D.C. & Moellering, R.C. Antimicrobial agents. In: Murray, P.R. et al. Manual of clinical microbiology. 7.ed. Washington: American Society for Microbiology, 1991. Vol. 116, p. 1474-504.
42. Zaoutis, T. et al. Antibiotics susceptibilities of group C and G Streptococci isolated from patients with invasive infections: evidence of vancomycin tolerance among group G serotypes. J. Clin. Microbiol., 37: 3380-3, 1999.